Concepts (263)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking Cessation | 25 | 2023 | 1032 | 5.800 |
Why?
|
| Marijuana Smoking | 11 | 2023 | 108 | 4.260 |
Why?
|
| Cannabis | 12 | 2023 | 115 | 4.000 |
Why?
|
| Cigarette Smoking | 7 | 2022 | 104 | 3.390 |
Why?
|
| Marijuana Abuse | 13 | 2019 | 251 | 3.070 |
Why?
|
| Acetylcysteine | 14 | 2021 | 296 | 2.850 |
Why?
|
| Tobacco Use Disorder | 13 | 2023 | 432 | 2.740 |
Why?
|
| Smoking | 17 | 2021 | 1449 | 2.630 |
Why?
|
| Tobacco Use | 8 | 2022 | 98 | 2.560 |
Why?
|
| Tobacco Products | 9 | 2022 | 234 | 2.520 |
Why?
|
| Smokers | 9 | 2022 | 198 | 2.200 |
Why?
|
| Substance-Related Disorders | 12 | 2019 | 1241 | 1.790 |
Why?
|
| Electronic Nicotine Delivery Systems | 3 | 2023 | 180 | 1.590 |
Why?
|
| Vaping | 3 | 2022 | 124 | 1.580 |
Why?
|
| Dextroamphetamine | 5 | 2011 | 30 | 1.460 |
Why?
|
| Varenicline | 7 | 2020 | 98 | 1.390 |
Why?
|
| Young Adult | 30 | 2023 | 5708 | 1.370 |
Why?
|
| Adult | 54 | 2023 | 21375 | 1.370 |
Why?
|
| Nicotine | 7 | 2023 | 350 | 1.350 |
Why?
|
| Discrimination Learning | 6 | 2011 | 45 | 1.320 |
Why?
|
| Cell Phone | 3 | 2018 | 43 | 1.190 |
Why?
|
| Quinoxalines | 4 | 2015 | 78 | 1.140 |
Why?
|
| Benzazepines | 4 | 2015 | 104 | 1.120 |
Why?
|
| Carbon Monoxide | 3 | 2021 | 58 | 1.120 |
Why?
|
| Tobacco Use Cessation | 2 | 2023 | 44 | 1.090 |
Why?
|
| Adolescent | 31 | 2023 | 8903 | 1.050 |
Why?
|
| Behavior, Addictive | 5 | 2023 | 317 | 0.980 |
Why?
|
| Humans | 72 | 2023 | 68525 | 0.980 |
Why?
|
| Female | 57 | 2022 | 38015 | 0.980 |
Why?
|
| Marijuana Use | 3 | 2020 | 35 | 0.970 |
Why?
|
| Breath Tests | 2 | 2021 | 23 | 0.960 |
Why?
|
| Stress, Psychological | 6 | 2020 | 824 | 0.940 |
Why?
|
| Nicotinic Agonists | 5 | 2015 | 111 | 0.910 |
Why?
|
| Smartphone | 2 | 2021 | 69 | 0.900 |
Why?
|
| Alcohol Drinking | 6 | 2020 | 805 | 0.900 |
Why?
|
| Hallucinogens | 1 | 2023 | 14 | 0.890 |
Why?
|
| Male | 51 | 2022 | 37281 | 0.870 |
Why?
|
| Columbidae | 8 | 2011 | 12 | 0.830 |
Why?
|
| Craving | 4 | 2020 | 200 | 0.820 |
Why?
|
| Counseling | 3 | 2019 | 279 | 0.810 |
Why?
|
| Smoking Prevention | 6 | 2018 | 259 | 0.810 |
Why?
|
| Oxytocin | 2 | 2020 | 124 | 0.800 |
Why?
|
| Self Report | 8 | 2022 | 370 | 0.780 |
Why?
|
| Conditioning, Operant | 4 | 2010 | 241 | 0.770 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2019 | 467 | 0.700 |
Why?
|
| Mobile Applications | 2 | 2018 | 138 | 0.690 |
Why?
|
| Ecological Momentary Assessment | 2 | 2018 | 16 | 0.690 |
Why?
|
| Tobacco | 5 | 2023 | 161 | 0.670 |
Why?
|
| Stress, Physiological | 1 | 2020 | 215 | 0.670 |
Why?
|
| Middle Aged | 29 | 2022 | 21119 | 0.670 |
Why?
|
| Telemedicine | 4 | 2022 | 699 | 0.660 |
Why?
|
| Data Collection | 2 | 2018 | 420 | 0.660 |
Why?
|
| Digital Divide | 1 | 2018 | 2 | 0.660 |
Why?
|
| Central Nervous System Stimulants | 4 | 2009 | 221 | 0.650 |
Why?
|
| Cues | 9 | 2020 | 654 | 0.650 |
Why?
|
| Medication Adherence | 5 | 2020 | 335 | 0.630 |
Why?
|
| Sex Characteristics | 1 | 2019 | 295 | 0.610 |
Why?
|
| Monitoring, Ambulatory | 1 | 2018 | 84 | 0.610 |
Why?
|
| Internet | 4 | 2016 | 390 | 0.600 |
Why?
|
| United States | 14 | 2023 | 7335 | 0.600 |
Why?
|
| Research Design | 4 | 2019 | 729 | 0.590 |
Why?
|
| Poverty | 1 | 2018 | 218 | 0.590 |
Why?
|
| Mothers | 1 | 2018 | 172 | 0.580 |
Why?
|
| Inpatients | 1 | 2017 | 208 | 0.550 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 424 | 0.520 |
Why?
|
| Social Environment | 4 | 2020 | 182 | 0.520 |
Why?
|
| Substance Withdrawal Syndrome | 7 | 2019 | 435 | 0.510 |
Why?
|
| Progesterone | 3 | 2022 | 115 | 0.500 |
Why?
|
| Extinction, Psychological | 3 | 2019 | 240 | 0.480 |
Why?
|
| Memory Disorders | 1 | 2015 | 111 | 0.470 |
Why?
|
| Treatment Outcome | 15 | 2019 | 7028 | 0.460 |
Why?
|
| Microcomputers | 1 | 2012 | 32 | 0.450 |
Why?
|
| Electronic Mail | 1 | 2012 | 29 | 0.440 |
Why?
|
| Time Factors | 8 | 2018 | 4655 | 0.440 |
Why?
|
| Reinforcement Schedule | 3 | 2009 | 59 | 0.430 |
Why?
|
| Adolescent Behavior | 1 | 2015 | 264 | 0.430 |
Why?
|
| Motivation | 3 | 2019 | 561 | 0.420 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 766 | 0.410 |
Why?
|
| Haloperidol | 1 | 2011 | 95 | 0.390 |
Why?
|
| Double-Blind Method | 8 | 2019 | 1737 | 0.390 |
Why?
|
| Behavior Therapy | 4 | 2019 | 297 | 0.380 |
Why?
|
| Medical Marijuana | 2 | 2022 | 21 | 0.380 |
Why?
|
| Photic Stimulation | 2 | 2010 | 229 | 0.370 |
Why?
|
| Administration, Intranasal | 2 | 2020 | 88 | 0.360 |
Why?
|
| Communication | 1 | 2012 | 329 | 0.360 |
Why?
|
| Health Care Surveys | 2 | 2022 | 239 | 0.340 |
Why?
|
| Time Perception | 2 | 2006 | 9 | 0.340 |
Why?
|
| Cross-Sectional Studies | 7 | 2022 | 2264 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2015 | 1745 | 0.330 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 848 | 0.330 |
Why?
|
| Surveys and Questionnaires | 6 | 2022 | 2798 | 0.320 |
Why?
|
| Feasibility Studies | 3 | 2022 | 652 | 0.310 |
Why?
|
| Behavior, Animal | 2 | 2009 | 470 | 0.310 |
Why?
|
| Sex Factors | 7 | 2020 | 1265 | 0.310 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2020 | 71 | 0.310 |
Why?
|
| Cotinine | 2 | 2021 | 40 | 0.300 |
Why?
|
| Intimate Partner Violence | 2 | 2020 | 58 | 0.300 |
Why?
|
| Alcoholism | 3 | 2022 | 1109 | 0.290 |
Why?
|
| Estradiol | 2 | 2020 | 176 | 0.290 |
Why?
|
| Anxiety | 3 | 2017 | 422 | 0.280 |
Why?
|
| Patient Compliance | 4 | 2019 | 402 | 0.280 |
Why?
|
| Recurrence | 2 | 2019 | 948 | 0.280 |
Why?
|
| Age Factors | 4 | 2019 | 1860 | 0.280 |
Why?
|
| Prevalence | 3 | 2020 | 1609 | 0.280 |
Why?
|
| Drug-Seeking Behavior | 2 | 2019 | 213 | 0.270 |
Why?
|
| Pilot Projects | 3 | 2022 | 1341 | 0.270 |
Why?
|
| Depression | 4 | 2019 | 942 | 0.260 |
Why?
|
| Free Radical Scavengers | 4 | 2019 | 112 | 0.260 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 955 | 0.240 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 2 | 2014 | 19 | 0.230 |
Why?
|
| Outpatients | 2 | 2014 | 127 | 0.230 |
Why?
|
| Saliva | 2 | 2022 | 142 | 0.220 |
Why?
|
| Animals | 11 | 2019 | 20877 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 929 | 0.220 |
Why?
|
| Opiate Substitution Treatment | 2 | 2013 | 57 | 0.220 |
Why?
|
| Tobacco Smoking | 2 | 2020 | 41 | 0.220 |
Why?
|
| Reaction Time | 4 | 2006 | 170 | 0.210 |
Why?
|
| Confidentiality | 2 | 2022 | 62 | 0.210 |
Why?
|
| Pregnancy | 2 | 2018 | 2331 | 0.210 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 3256 | 0.200 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 567 | 0.190 |
Why?
|
| Neuroendocrine Cells | 1 | 2020 | 8 | 0.190 |
Why?
|
| Neurosecretory Systems | 1 | 2020 | 21 | 0.190 |
Why?
|
| Harm Reduction | 1 | 2020 | 21 | 0.190 |
Why?
|
| Consensus | 1 | 2021 | 211 | 0.180 |
Why?
|
| Primary Health Care | 2 | 2023 | 702 | 0.180 |
Why?
|
| Luteal Phase | 2 | 2022 | 25 | 0.180 |
Why?
|
| Menstrual Cycle | 2 | 2022 | 64 | 0.180 |
Why?
|
| ROC Curve | 1 | 2021 | 392 | 0.180 |
Why?
|
| Comorbidity | 3 | 2019 | 1425 | 0.180 |
Why?
|
| Family Characteristics | 1 | 2020 | 44 | 0.180 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2020 | 150 | 0.180 |
Why?
|
| Pituitary-Adrenal System | 1 | 2020 | 138 | 0.180 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 517 | 0.180 |
Why?
|
| Smoking Devices | 1 | 2019 | 6 | 0.180 |
Why?
|
| Drug Tolerance | 3 | 2009 | 80 | 0.170 |
Why?
|
| Drug Substitution | 1 | 2018 | 19 | 0.170 |
Why?
|
| False Negative Reactions | 1 | 2019 | 63 | 0.170 |
Why?
|
| Physicians, Women | 1 | 2018 | 23 | 0.170 |
Why?
|
| Hydrocortisone | 1 | 2020 | 291 | 0.170 |
Why?
|
| Staff Development | 1 | 2018 | 35 | 0.160 |
Why?
|
| Research | 1 | 2019 | 214 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2022 | 374 | 0.160 |
Why?
|
| Postpartum Period | 1 | 2018 | 67 | 0.160 |
Why?
|
| Southeastern United States | 1 | 2018 | 281 | 0.160 |
Why?
|
| Biomarkers | 3 | 2018 | 1593 | 0.160 |
Why?
|
| Faculty, Medical | 1 | 2018 | 110 | 0.160 |
Why?
|
| Health Services Research | 1 | 2019 | 209 | 0.150 |
Why?
|
| Sleep | 2 | 2017 | 263 | 0.150 |
Why?
|
| Leadership | 1 | 2018 | 135 | 0.150 |
Why?
|
| Ambulatory Care | 3 | 2014 | 339 | 0.150 |
Why?
|
| Video Recording | 1 | 2018 | 145 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1548 | 0.150 |
Why?
|
| Cannabinoids | 1 | 2017 | 90 | 0.150 |
Why?
|
| Attention | 2 | 2011 | 225 | 0.150 |
Why?
|
| Telephone | 1 | 2017 | 160 | 0.150 |
Why?
|
| Crime Victims | 1 | 2020 | 286 | 0.150 |
Why?
|
| Urban Population | 1 | 2018 | 254 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 281 | 0.140 |
Why?
|
| Underage Drinking | 1 | 2016 | 25 | 0.140 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2016 | 57 | 0.140 |
Why?
|
| Saccades | 2 | 2006 | 17 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 170 | 0.140 |
Why?
|
| South Carolina | 2 | 2020 | 2750 | 0.130 |
Why?
|
| Antioxidants | 1 | 2017 | 304 | 0.130 |
Why?
|
| Gender Identity | 1 | 2015 | 47 | 0.130 |
Why?
|
| Follicular Phase | 1 | 2014 | 15 | 0.130 |
Why?
|
| Suicide | 1 | 2016 | 115 | 0.130 |
Why?
|
| Smoke-Free Policy | 1 | 2014 | 8 | 0.130 |
Why?
|
| Frontal Lobe | 1 | 2015 | 156 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2017 | 621 | 0.120 |
Why?
|
| Administration, Cutaneous | 1 | 2013 | 56 | 0.120 |
Why?
|
| Corpus Striatum | 1 | 2015 | 278 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 137 | 0.120 |
Why?
|
| Patient Participation | 1 | 2015 | 145 | 0.120 |
Why?
|
| Neural Pathways | 1 | 2015 | 323 | 0.120 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2014 | 127 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2014 | 411 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2014 | 159 | 0.110 |
Why?
|
| Aged | 3 | 2022 | 14842 | 0.110 |
Why?
|
| Psychotropic Drugs | 1 | 2013 | 83 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 447 | 0.110 |
Why?
|
| Social Support | 2 | 2013 | 423 | 0.110 |
Why?
|
| Computer Literacy | 1 | 2012 | 9 | 0.110 |
Why?
|
| Analysis of Variance | 3 | 2013 | 1039 | 0.110 |
Why?
|
| Molecular Structure | 1 | 2014 | 397 | 0.110 |
Why?
|
| Text Messaging | 1 | 2012 | 47 | 0.110 |
Why?
|
| Computer-Assisted Instruction | 1 | 2011 | 74 | 0.100 |
Why?
|
| Dopamine Antagonists | 1 | 2011 | 65 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2016 | 659 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2011 | 172 | 0.100 |
Why?
|
| Sulfasalazine | 1 | 2010 | 3 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2012 | 291 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 177 | 0.090 |
Why?
|
| Community Health Services | 1 | 2011 | 141 | 0.090 |
Why?
|
| Reward | 1 | 2012 | 201 | 0.090 |
Why?
|
| Injections, Intramuscular | 1 | 2009 | 44 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2020 | 3702 | 0.090 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2011 | 152 | 0.090 |
Why?
|
| Psychophysics | 1 | 2009 | 30 | 0.090 |
Why?
|
| Opioid-Related Disorders | 1 | 2013 | 298 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2077 | 0.080 |
Why?
|
| Quality of Life | 1 | 2017 | 1515 | 0.080 |
Why?
|
| Logistic Models | 1 | 2012 | 1419 | 0.080 |
Why?
|
| Random Allocation | 1 | 2009 | 442 | 0.080 |
Why?
|
| Dronabinol | 2 | 2019 | 84 | 0.080 |
Why?
|
| Mass Screening | 1 | 2013 | 837 | 0.080 |
Why?
|
| Amphetamine | 1 | 2007 | 77 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2222 | 0.070 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 1506 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2019 | 2083 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2005 | 737 | 0.060 |
Why?
|
| Algorithms | 2 | 2007 | 1194 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2020 | 7264 | 0.050 |
Why?
|
| Peer Review | 1 | 2022 | 16 | 0.050 |
Why?
|
| Sexism | 1 | 2022 | 11 | 0.050 |
Why?
|
| Hotlines | 1 | 2022 | 51 | 0.050 |
Why?
|
| Documentation | 1 | 2022 | 83 | 0.050 |
Why?
|
| Probability | 1 | 2021 | 244 | 0.050 |
Why?
|
| Rats | 2 | 2019 | 5300 | 0.050 |
Why?
|
| Drug Users | 1 | 2020 | 10 | 0.050 |
Why?
|
| Aging | 1 | 2006 | 911 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2013 | 782 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 1054 | 0.040 |
Why?
|
| Estrous Cycle | 1 | 2019 | 23 | 0.040 |
Why?
|
| Career Mobility | 1 | 2018 | 34 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 123 | 0.040 |
Why?
|
| Dendritic Spines | 1 | 2019 | 76 | 0.040 |
Why?
|
| Career Choice | 1 | 2018 | 98 | 0.040 |
Why?
|
| Sulpiride | 1 | 2017 | 20 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 521 | 0.040 |
Why?
|
| Program Development | 1 | 2018 | 240 | 0.040 |
Why?
|
| Psychomotor Performance | 2 | 2011 | 213 | 0.040 |
Why?
|
| Self Administration | 1 | 2019 | 419 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 5719 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 951 | 0.040 |
Why?
|
| Behavior | 1 | 2016 | 59 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2018 | 502 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2019 | 274 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2019 | 332 | 0.030 |
Why?
|
| Psychiatry | 1 | 2016 | 112 | 0.030 |
Why?
|
| Transdermal Patch | 1 | 2015 | 21 | 0.030 |
Why?
|
| Nucleus Accumbens | 1 | 2019 | 417 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 592 | 0.030 |
Why?
|
| Baltimore | 1 | 2014 | 34 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1582 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 563 | 0.030 |
Why?
|
| Women's Health | 1 | 2015 | 148 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 488 | 0.030 |
Why?
|
| Arousal | 1 | 2014 | 168 | 0.030 |
Why?
|
| Social Media | 1 | 2015 | 58 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1465 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 279 | 0.030 |
Why?
|
| Affect | 1 | 2013 | 218 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2550 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2013 | 326 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 503 | 0.020 |
Why?
|
| Cognition | 1 | 2011 | 512 | 0.020 |
Why?
|
| Association Learning | 1 | 2005 | 36 | 0.020 |
Why?
|
| Motor Skills | 1 | 2006 | 88 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 306 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2005 | 240 | 0.020 |
Why?
|
| Child | 1 | 2005 | 6400 | 0.010 |
Why?
|